Navigation Links
Mirati Therapeutics Reports Third Quarter 2013 Financial Results
Date:11/12/2013

$34,000 for the same period in 2012. Other expense, net in the first nine months of 2013 was a $17.4 million compared to other income, net of $172,000 for the same period in 2012. The net expense for both periods of 2013 primarily reflects expense arising from the change in fair value of our warrant liability.

Net loss and comprehensive loss for the third quarter ended September 30, 2013 was $29.4 million, or $2.95 per share, compared to net loss and comprehensive loss of $5.9 million, or $0.93 per share, for the same period last year. Net loss and comprehensive loss for the first nine months of 2013 was $41.6 million, or $4.18 per share, compared to net loss and comprehensive loss of $14.0 million, or $2.20 per share, for the same period in 2012.

About Mirati Therapeutics
Mirati Therapeutics is a targeted oncology company developing an advanced pipeline of breakthrough medicines for precisely defined patient populations. Mirati's approach combines the three most important factors in oncology drug development - drug candidates with complementary and compelling targets, creative and agile clinical development, and a highly accomplished precision medicine leadership team. The Mirati team is using its proven blueprint for developing targeted oncology medicines to advance and maximize the value of its pipeline of drug candidates. More information is available at www.mirati.com.

Forward Looking Statements
Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking information and forward-looking statements (collectively "forward-looking statements" within the meaning of applicable securities laws). Such statements, based as they are on the current expectations of management of Mirati and upon what management believes to be reasonable assumptions based on information currently available to it, inherentl
'/>"/>

SOURCE Mirati Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Mirati Therapeutics Prices Public Offering Of Common Stock
2. Sorrento Therapeutics Adopts Stockholder Rights Plan
3. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
4. Shield Therapeutics Files Investigational New Drug Application for ST10 for the Treatment of Iron Deficiency in Chronic Kidney Disease
5. Cara Therapeutics Files Registration Statement for Proposed Initial Public Offering
6. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
7. Echo Therapeutics Announces Third Quarter 2013 Financial Results
8. Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference
9. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
10. PDL BioPharma Provides $70 Million in Financing to Durata Therapeutics
11. PTC Therapeutics to Present at Credit Suisse Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015  HyGreen, Inc., a leader in hand ... with RCA Medical, a subsidiary of Ascendis Health Limited, ... Each year, hundreds of millions of patients around ... organisms are transmitted from patient to patient via the ...
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
(Date:1/23/2015)... N.J. , Jan. 23, 2015  CytoSorbents Corporation ... commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce ... announced the receipt of $385,642, net of transaction ... of the Technology Business Tax Certificate Transfer Program ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
... Tim Wentworth, group president for employer and key ... MHS ), is scheduled to present at the Lazard ... 17, 2010 in New York. (Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO) ... The St. Regis Hotel is scheduled to begin at ...
... Despite national guidelines recommending that inhaled corticosteroid (ICS) ... with mild persistent asthma, a new study finds that ... drugs that combine an ICS and a long-acting beta ... noted based on pharmacy and medical claims. The analysis ...
Cached Medicine Technology:Medco to Present at the Lazard Capital Markets 7th Annual Healthcare Conference 2New Study: Overuse of Combination Drug Therapy in Patients with Mild Asthma Leads to Increased Costs 2New Study: Overuse of Combination Drug Therapy in Patients with Mild Asthma Leads to Increased Costs 3New Study: Overuse of Combination Drug Therapy in Patients with Mild Asthma Leads to Increased Costs 4
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort ... as the number one best large hotel for families in ... for their annual Travelers’ Choice Awards. , TripAdvisor represents ... is home to millions of unbiased and honest traveler reviews. ...
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in ... Player Health Alliance (PPHA). The PPHA's passion for others' ... including NFL greats, treated for obstructive sleep apnea (OSA) has ... the cause in the valley. The most recent plans for ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put together by ... up to 30lbs in less than 12 weeks without traditional ... prompting an investigative review. , “Our Incredible Bulk review ... that allows the body to pack on a massive amount ...
(Date:1/22/2015)... 22, 2015 Blue Cross and Blue Shield ... exemplify what it means to “Live Fearless.” , ... to share their stories about how they or someone they ... others by living in the moment. By telling these types ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The federal court ... the U.S. District Court, Southern District of West Virginia has ... in that proceeding’s first bellwether trial. In an Order dated ... new trial after finding that C.R. Bard had not proven ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4
... Boys with asthma who are exposed to environmental tobacco ... other behavioral problems, according to researchers at Cincinnati Children,s ... ahead of print by the Journal of Developmental ... increase along with higher exposure levels, but they added ...
... Transgenomic,(OTC Bulletin Board: TBIO) today announced ... Texas through its technology transfer entity, the,Research ... exclusive license,to patents covering a method for ... the basis for the development of diagnostic ...
... - Over 11,000 people raced to wellness in Louisiana ... challenge event was the latest in a series of programs ... is part of a growing movement to help people live ... one of the country,s most obese states, Louisiana is continuing ...
... (Dec. 4, 2008) In a statewide survey of ... Research Institute at Harbor-UCLA Medical Center (LA BioMed) are ... according to the December issue of Los Angeles magazine. ... more than 30,000 medical professionals to compile the 2008 ...
... released the following statement in reaction to the latest Congressional ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070209/NYF043LOGO ) , ... that will only get worse if we allow America,s biggest ... these corporations go under -- taking with them the men ...
... division of Patient Safety Technologies, Inc. (OTC Bulletin Board:,PSTX), today ... become,one of its partners in helping to create a safer, ... at Leapfrog,s next two meetings in,December and February. , ... privileged to enter into an affiliation with,Leapfrog. We share a ...
Cached Medicine News:Health News:Study strengthens link between tobacco smoke and behavioral problems in boys with asthma 2Health News:Study strengthens link between tobacco smoke and behavioral problems in boys with asthma 3Health News:Transgenomic Obtains Exclusive License to Mitochondrial DNA Damage Detection Technology 2Health News:Transgenomic Obtains Exclusive License to Mitochondrial DNA Damage Detection Technology 3Health News:Transgenomic Obtains Exclusive License to Mitochondrial DNA Damage Detection Technology 4Health News:Transgenomic Obtains Exclusive License to Mitochondrial DNA Damage Detection Technology 5Health News:Transgenomic Obtains Exclusive License to Mitochondrial DNA Damage Detection Technology 6Health News:High Tech Wellness Inspires Louisiana 2Health News:LA BioMed researchers among Southern California Super Doctors 2Health News:AARP: Health Care and Pension Reform Critical to Economic Recovery 2Health News:AARP: Health Care and Pension Reform Critical to Economic Recovery 3Health News:SurgiCount Medical Joins The Leapfrog Group 2
9mm Curved Blades with Sharp Pointed Tips; overall length 90mm; Stainless Steel....
3 Gently Curved Prongs, 5mm extended, Stainless Steel Tips; with titanium handle....
Straight shafts with fine Pierse type tips on a 5mm platform; In Titanium...
Straight shaft; a 5mm platform with 0.3mm 1x2 teeth; In Titanium....
Medicine Products: